Advertisement
Advertisement
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
4.03
USDSponsored
-0.21
-4.95%
Oct 30, 16:00 UTC -4
Closed
After-Market
4.03
0.00
+0.07%
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Earnings
RXRX Earnings Reports
Positive Surprise Ratio
RXRX beat 13 of 21 last estimates.
62%
Next Report
Next Week
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$15.08M
/-$0.23
Implied change from Q2 26 (Revenue/ EPS)
+96.59%
/-8.00%
Implied change from Q3 25 (Revenue/ EPS)
+191.37%
/-36.11%
Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On Aug 05, 2026, RXRX reported earnings of -0.25 USD per share (EPS) for Q2 26, missing the estimate of -0.23 USD, resulting in a -4.73% surprise. Revenue reached 7.67 million, compared to an expected 12.19 million, with a -37.06% difference. The market reacted with a -4.23% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.23 USD, with revenue projected to reach 15.08 million USD, implying an decrease of -8.00% EPS, and increase of 96.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
PTC Therapeutics, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.34
Actual
$0.61
Surprise
+75.59%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
FAQ
What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.25, missing estimates by -4.73%, and revenue of $7.67M, -37.06% below expectations.
How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved down -4.23%, changed from $3.31 before the earnings release to $3.17 the day after.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 7
analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.23 and revenue of $15.08M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.